Medical and psychosocial issues in prostate cancer survivors

Cancer Survivorship: Today and Tomorrow

Volumn , Issue , 2007, Pages 145-156

  Krupski, Tracey L ^a   Litwin, Mark S ^b  

^a University School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872050749     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68265-5_12     Document Type: Chapter

References (221)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7-33.
3. Osoba D. Measuring the effect of cancer on quality of life. In: Osoba D (ed). Effect of Cancer on Quality of Life. Boca Raton: CRC Press, 1991:25-40.
4. Penson DF, Litwin MS. The Impact of Urologic Complications on Quality of Life. In: Taneja SS, Smith RB, Ehrlich RM, (eds). Complications of Urologic Surgery, 3rd edition. Philadelphia PA: WB Saunders and Co., 2000:56-66.
5. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer (Phila) 1998; 82(10):1904-1908.
6. Roth A, Scher H. Genitourinary malignancies. In: Holland JC (ed). Psycho-oncology. New York: Oxford University Press, 1998: 39-358.
7. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991;146(5):1305-1307.
8. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46(1):5-27.
9. Gilliland FD, Key CR. Prostate cancer in American Indians, New Mexico, 1969 to 1994. J Urol 1998;159(3):893-897; discussion 897-898.
10. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93(5):388-395.
11. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004;171(4):1504-1507.
12. Nayeri K, Pitaro G, Feldman JG. Marital status and stage at diagnosis in cancer. N Y State J Med 1992;92(1):8-11.
13. Harvei S, Kravdal O. The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts. Prev Med 1997;26(5 pt 1):623-632.
14. ACS. Cancer Facts and Figures. Washington, DC: American Cancer Society, 2003.
15. Zietman A, Moughan J, Owen J, Hanks G. The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys 2001;50(1):75-80.
16. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer (Phila) 2000;88(10):2398-2424.
17. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8(12):1117-1121.
18. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76(1):45-48.
19. Hargraves JL, Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Serv Res 2003;38(3):809-829.
20. Cunningham PJ, Kemper P. The uninsured getting care: where you live matters. Issue Brief Cent Stud Health Syst Change 1998(15):1-6.
21. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-974.
22. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-789.
23. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
24. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21(11):2163-2172.
25. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 pt 2):1837-1842.
26. Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Tenyear biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57(4):944-952.
27. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49(5): 282-296.
28. Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156(5): 1707-1713.
29. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 pt 2):1831-1836.
30. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14(8):2258-2265.
31. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346(15):1138-1144.
32. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21(3):401-405.
33. Walsh PC, Partin AW. Treatment of early stage prostate cancer: radical prostatectomy. Important Adv Oncol 1994:211-223.
34. Wei JT, Montie JE. Comparison of patients' and physicians' rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol 2000;18(1):76-80.
35. Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999;17(9):2882-2888.
36. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998;159(6):1988-1992.
37. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54(3):503-508.
38. Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000;164(6):1973-1977.
39. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer (Phila) 2001;91(11):2046-2055.
40. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55(1):58-61.
41. Wei JT, Dunn RL, Marcovish R, et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000;164(3):744-748.
42. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997;89(15):1117-1123.
43. Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer (Phila) 2000;88(6):1454-1463.
44. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol 2003;170(4 pt 1):1291-1294.
45. Leach GE, Trockman B, Wong A, Hamilton J, Haab F, Zimmern PE. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 1996;155(4):1256-1259.
46. Haab F, Yamaguchi R, Leach GE. Postprostatectomy incontinence. Urol Clin N Am 1996;23(3):447-457.
47. Lightner DJ. Review of the available urethral bulking agents. Curr Opin Urol 2002;12(4):333-338.
48. Smith DN, Appell RA, Rackley RR, Winters JC. Collagen injection therapy for post-prostatectomy incontinence. J Urol 1998;160(2):364-367.
49. Cross CA, English SF, Cespedes RD, McGuire EJ. A follow-up on transurethral collagen injection therapy for urinary incontinence. J Urol 1998;159(1):106-108.
50. Montague DK, Angermeier KW. Postprostatectomy urinary incontinence: the case for artificial urinary sphincter implantation. Urology 2000;55(1):2-4.
51. Montague DK, Angermeier KW. Artificial urinary sphincter troubleshooting. Urology 2001;58(5):779-782.
52. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273(2): 129-135.
53. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42(6):622-629.
54. Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF. Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy. Prostate Cancer Prostatic Dis 1998;1(5):242-249.
55. Cohn JH, El-Galley R. Radical prostatectomy in a community practice. J Urol 2002;167(1):224-228.
56. Uckert S, Hedlund P, Waldkirch E, et al. Interactions between cGMP-and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol 2004;22(4):261-266.
57. Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000;55(2):241-245.
58. Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000;56(4):631-634.
59. Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160(4):1325-1328.
60. Rodriguez VGI, Bona, AA, Benejam GJ, Cuesta P, Jioja Sanz LA. Erectile dysfunction after radical prostatectomy etiopathology and treatment. Acta Urol Esp 1997;21:909-921.
61. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 1995;22(4):833-845.
62. Soderdahl DW, Thrasher JB, Hansberry KL. Intracavernosal druginduced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997;79(6):952-957.
63. Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43(2):95-101; discussion 101-102.
64. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000;164(2):376-380.
65. Geary ES, Dendinger TE, Freiha FS, Stamey TA. Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45(6):1000-1006.
66. Kochakarn W, Ratana-Olarn K, Viseshsindh V. Vesicourethral strictures after radical prostatectomy: review of treatment and outcome. J Med Assoc Thai 2002;85(1):63-66.
67. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(5):1260-1268.
68. Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43(2):385-391.
69. Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998;51(6): 991-997.
70. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48(3):635-642.
71. Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapyrelated fatigue: how to assess and how to treat the symptom. A commentary. Tumori 2001;87(3):147-151.
72. Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000;89(6):1322-1328.
73. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002;8(1):67-73.
74. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41(4):427-433.
75. Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Invest 1999;7(5):278-288.
76. Peschel RE, Colberg JW. Surgery, brachytherapy, and externalbeam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4(4):233-241.
77. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45(1):59-67.
78. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48(1):119-124.
79. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50(2):335-341.
80. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54(3):503-508.
81. Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000;164(6):1973-1977.
82. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer (Phila) 2001;91(11):2046-2055.
83. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55(1):58-61.
84. Wei JT, Dunn RL, Marcovish R, et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000;164(3):744-748.
85. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997;89(15):1117-1123.
86. Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer (Phila) 2000;88(6):1454-1463.
87. Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol 2003;170(4 pt 1):1291-1294.
88. Leach GE, Trockman B, Wong A, Hamilton J, Haab F, Zimmern PE. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 1996;155(4):1256-1259.
89. Haab F, Yamaguchi R, Leach GE. Postprostatectomy incontinence. Urol Clin N Am 1996;23(3):447-457.
90. Lightner DJ. Review of the available urethral bulking agents. Curr Opin Urol 2002;12(4):333-338.
91. Smith DN, Appell RA, Rackley RR, Winters JC. Collagen injection therapy for post-prostatectomy incontinence. J Urol 1998;160(2):364-367.
92. Cross CA, English SF, Cespedes RD, McGuire EJ. A follow-up on transurethral collagen injection therapy for urinary incontinence. J Urol 1998;159(1):106-108.
93. Montague DK, Angermeier KW. Postprostatectomy urinary incontinence: the case for artificial urinary sphincter implantation. Urology 2000;55(1):2-4.
94. Montague DK, Angermeier KW. Artificial urinary sphincter troubleshooting. Urology 2001;58(5):779-782.
95. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273(2): 129-135.
96. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42(6):622-629.
97. Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF. Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy. Prostate Cancer Prostatic Dis 1998;1(5):242-249.
98. Cohn JH, El-Galley R. Radical prostatectomy in a community practice. J Urol 2002;167(1):224-228.
99. Uckert S, Hedlund P, Waldkirch E, et al. Interactions between cGMP-and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol 2004;22(4):261-266.
100. Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000;55(2):241-245.
101. Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000;56(4):631-634.
102. Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160(4):1325-1328.
103. Rodriguez VGI, Bona, AA, Benejam GJ, Cuesta P, Jioja Sanz LA. Erectile dysfunction after radical prostatectomy etiopathology and treatment. Acta Urol Esp 1997;21:909-921.
104. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 1995;22(4):833-845.
105. Soderdahl DW, Thrasher JB, Hansberry KL. Intracavernosal druginduced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997;79(6):952-957.
106. Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43(2):95-101; discussion 101-102.
107. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000;164(2):376-380.
108. Geary ES, Dendinger TE, Freiha FS, Stamey TA. Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45(6):1000-1006.
109. Kochakarn W, Ratana-Olarn K, Viseshsindh V. Vesicourethral strictures after radical prostatectomy: review of treatment and outcome. J Med Assoc Thai 2002;85(1):63-66.
110. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(5):1260-1268.
111. Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43(2):385-391.
112. Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998;51(6): 991-997.
113. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48(3):635-642.
114. Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapyrelated fatigue: how to assess and how to treat the symptom. A commentary. Tumori 2001;87(3):147-151.
115. Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000;89(6):1322-1328.
116. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002;8(1):67-73.
117. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41(4):427-433.
118. Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Invest 1999;7(5):278-288.
119. Peschel RE, Colberg JW. Surgery, brachytherapy, and externalbeam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4(4):233-241.
120. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45(1):59-67.
121. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48(1):119-124.
122. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50(2):335-341. medical and psychosocial issues in prostate cancer survivors 153
123. Merrick GS, Butler WM, Tollenaar BG, Galbreath RW, Lief JH. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002;52(2):461-468.
124. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology 2000;55(1): 91-96.
125. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50(5):1235-1242.
126. Stutz MA, Gurel MH, Moran BJ. Potency preservation after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 57(suppl 2):S393-S394.
127. Merrick GS, Butler WM, Lief JH, Dorsey AT. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol 2001;7(1):12-19.
128. Raina R, Agarwal A, Goyal KK, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003;62(6):1103-1108.
129. Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998;160(1):91-95; discussion 95-96.
130. Jordan GH, Lynch DF, Warden SS, McCraw JD, Hoffman GC, Schellhammer PF. Major rectal complications following interstitial implantation of 125iodine for carcinoma of the prostate. J Urol 1985;134(6):1212-1214.
131. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000;89(10):2085-2091.
132. Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57(3):273-278.
133. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer (Phila) 2002;95(2): 281-286.
134. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284(10):1280-1283.
135. D'Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 2000;163(6): 1797-1801.
136. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166(2):494-499.
137. Ghaly M, Wallner K, Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003;55(5): 1288-1293.
138. Wang H, Wallner K, Sutlief S, Blasko J, Russell K, Ellis W. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer 2000;90(4):199-205.
139. Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int 2003;91(4):345-349.
140. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Prostate Cancer Prostatic Dis 1999;2(S3):S32.
141. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer: data from CaPSURE. J Urol 2003;170(5):1822-1827.
142. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20(2):557-566.
143. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatmentrelated, demographic, and psychosocial factors. Cancer (Phila) 2001;92(6):1451-1459.
144. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166(3):947-952.
145. Van Andel G, Visser AP, Hulshof MC, Horenblas S, Kurth KH. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int 2003;92(3):217-222.
146. Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time tradeoff utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002;11(5):405-414.
147. Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract 1999;7(3):130-135.
148. Baider L, Walach N, Perry S, Kaplan De-Nour A. Cancer in married couples: higher or lower distress? J Psychosom Res 1998;45(3):239-248.
149. Hagedoorn M, Buunk BP, Kuijer RG, Wobbes T, Sanderman R. Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psycho-Oncology 2000;9(3):232-242.
150. Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. J Psychosom Res 1983;27(1): 77-83.
151. Greer S, Watson M. Towards a psychobiological model of cancer: psychological considerations. Soc Sci Med 1985;20(8):773-777.
152. Massie MJ, Shakin EJ. Management of depression and anxiety in the cancer patient. In: Breitbart W, Holland JC (eds). Psychiatric Aspects of Symptoms Management in Cancer Patients. Washington, DC: American Psychiatric Press, 1993:1-21.
153. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52(2):89-99.
154. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984;46(3):199-212.
155. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer (Phila) 1994; 73(11):2791-2802.
156. Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int 2002; 90(1):56-61.
157. Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int 2003;91(1):14-17.
158. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92(19):1582-1592.
159. Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. J Urol 2003;169(6):2279-2283.
160. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19(1):72-80.
161. Clark JA, Wray N, Brody B, Ashton C, Giesler B, Watkins H. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997;45(8):1299-1309.
162. Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 2003;170(5):1931-1933.
163. McNair DM, Lorr M, Droppleman CF. Manual: Profile of Mood States, 2nd ed. San Diego: Educational and Industrial Testing Service, 1981.
164. Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol 2003; 169(4):1449-1452.
165. Roth AJ, Rosenfeld B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer (Phila) 2003; 97(11):2910-2918.
166. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003;30(2):303-309.
167. Kaps EC. The role of the support group, "Us Too". Cancer (Phila) 1994;74(suppl 7):2188-2189.
168. Kunkel EJ, Bakker JR, Myers RE, Oyesanmi O, Gomella LG. Biopsychosocial aspects of prostate cancer. Psychosomatics 2000;41(2):85-94.
169. Austin JP, Aziz H, Potters L, et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol 1990;13(6):465-469.
170. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 pt 2): 1821-1825.
171. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 pt 2):1850-1857.
172. Abi-Aad AS, Macfarlane MT, Stein A, deKernion JB. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 1992;147(3 pt 2): 952-955.
173. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152(5 pt 2):1826-1830.
174. ASTRO. Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37: 1035-1041.
175. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1977; 37(1):82-94.
176. Schroder FH. Endocrine treatment of prostate cancer: recent developments and the future. Part 1: maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int 1999;83(2):161-170.
177. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502-508.
178. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999;36(suppl 2):20-26.
179. Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42(2):119-129; discussion 129-130.
180. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419-424.
181. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila) 1993;72(suppl 12):3888-3895.
182. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999(4):i-x, 1-246, I241-236, passim.
183. Bolla M, de Reijke TM, Zurlo A, Collette L. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. Front Radiat Ther Oncol 2002;36:81-86.
184. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24):1781-1788.
185. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16(1):87-116.
186. Niewoehner CB. Osteoporosis in men. Is it more common than we think? Postgrad Med 1993;93(8):59-60, 63-70.
187. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (Phila) 1997;79(3):545-550.
188. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormonereleasing hormone agonists for prostate cancer. BJU Int 2000;86(4):449-452.
189. Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol 2003;169(5):1747-1750.
190. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157(2):439-444.
191. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8): 1137-1141.
192. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106(3): 354-361.
193. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167(6):2361-2367; discussion 2367.
194. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948-955.
195. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin N Am 1998;27(2):349-367.
196. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58(2 suppl 1): 101-107.
197. Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003;170(6 pt 2):S59-S63; discussion S64.
198. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343(9):604-610.
199. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer (Phila) 1998;83(8):1561-1566.
200. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003;21(5):392-398.
201. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6): 2008-2012.
202. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(3 suppl 2):4-12.
203. Engelson ES, Rabkin JG, Rabkin R, Kotler DP. Effects of testosterone upon body composition. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(5):510-511.
204. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36(9):1134-1141.
205. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10): 1121-1123.
206. Stone P, Richards M, A'Hern R, Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manag 2001;22(6):1007-1015.
207. Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based study of fatigue and psychological distress. BMJ 1994;308(6931):763-766.
208. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933-941.
209. Herr HW, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer (Phila) 1993; 71(suppl 3):1143-1150.
210. Blanchard CG, Albrecht TL, Ruckdeschel JC. The crisis of cancer: psychological impact on family caregivers. Oncology (Williston Park) 1997;11(2):189-194; discussion 196, 201-202.
211. Valdimarsdottir U, Helgason AR, Furst CJ, Adolfsson J, Steineck G. The unrecognised cost of cancer patients' unrelieved symptoms: a nationwide follow-up of their surviving partners. Br J Cancer 2002;86(10):1540-1545.
212. Perry PJ, Yates WR, Williams RD, et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry 2002; 63(12):1096-1101.
213. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology 2002;11(6):518-523.
214. Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 2001;165(3): 871-875.
215. Melmed GY, Kwan L, Reid K, Litwin MS. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002;59(1):103-109.
216. Morris JN, Suissa S, Sherwood S, Wright SM, Greer D. Last days: a study of the quality of life of terminally ill cancer patients. J Chronic Dis 1986;39(1):47-62.
217. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000;284(19):2476-2482.
218. Saunders Y, Ross JR, Riley J. Planning for a good death: responding to unexpected events. BMJ 2003;327(7408):204-206; discussion 206-207.
219. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152(5 pt 2): 1817-1819.
220. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16(1):275-283.
221. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283(3): 354-360.